Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type1 V( i# l0 ]5 c( X. l- t
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
$ C* g5 e" t; D/ u9 x' z+ Author Affiliations( @7 i2 Y4 Z5 x ^1 C% j$ ~$ }
! w- ` j( }6 e
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
0 Q8 b0 m7 B* ^! E0 {$ \" F, W* q2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
& h. N" n1 y( u3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
+ j( }6 f& H' d* g4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan , [8 F7 i! A; S1 e4 w d
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
5 r# I' m2 ?0 E" t6 N0 k- g5 w! h6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan 7 L6 w+ B4 b% Y. W- g! c h
7Kinki University School of Medicine, Osaka 589-8511, Japan 9 G' P. x9 D" J! v4 e9 l7 }
8Izumi Municipal Hospital, Osaka 594-0071, Japan 3 x* x% i( _- M) Z) ~, q! c& D( v
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
3 I% S, W+ P, w2 lCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
7 L% O1 V* s h- u; A7 h/ ?( EAbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
5 t: w& i) @% _' t% i% t# m$ s! d1 e, D% _* f/ w
|